Athira Pharma Equity 2024

Athira Pharma Aktienanalyse

What does Athira Pharma do?

Athira Pharma Inc. is a biopharmaceutical company founded in 2011 and based in Seattle, USA. The company focuses on the development of therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. The strategy of Athira is to develop therapies for the treatment of diseases of the central nervous system and the regeneration of tissues that have been damaged by injuries or aging, based on RNA-based technologies. This work is carried out by an experienced team of scientists and executives. Athira's business model is based on the goal of developing innovative and personalized drug therapies to prevent, slow down, or specifically treat diseases. The company pursues an evidence-based approach called "patient-centered approach." Athira aims to understand the cause of certain diseases and develop targeted therapies that aim to treat that cause. Athira's research and development area consists of three units: 1. Neurology: This division focuses on the development of therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. The company has already developed a drug candidate that is in an extended phase I/II clinical trial and shows potential for the treatment of Alzheimer's dementia. 2. Regeneration: The regeneration division mainly deals with the regeneration of nerve cells and tissues in the body. This area has the potential to develop therapies for the treatment of spinal cord injuries and degenerative diseases of the body. 3. Platform technology: Athira's platform technologies are based on RNA interference technology, which aims to experimentally silence genes. The platform technology aims to identify and validate cell-specific RNA targets that can address a wide range of diseases. Athira specializes in the research and development of innovative therapies with the goal of defeating diseases and improving patients' health. The company has achieved significant successes in recent years, positioning itself as an important player in the industry. The market for therapies for the treatment of neurodegenerative diseases offers immense opportunities and potentials as these diseases are expected to increase in the future due to the aging population. Athira sees itself well positioned to take on the challenges in the industry and continue to develop innovative solutions for the treatment of diseases. Athira Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Athira Pharma's Equity

Athira Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Athira Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Athira Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Athira Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Athira Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Athira Pharma stock

What is the equity of Athira Pharma this year?

Athira Pharma has equity of 130.19 M USD this year.

What was the equity of Athira Pharma compared to the previous year?

The equity of Athira Pharma has increased/decreased by -44.62% decreased compared to the previous year.

What impact does a high equity have on investors of Athira Pharma?

A high equity is advantageous for investors of Athira Pharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Athira Pharma?

A low equity can be a risk for investors of Athira Pharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Athira Pharma affect the company?

An increase in equity of Athira Pharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Athira Pharma affect the company?

A reduction in equity of Athira Pharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Athira Pharma?

Some factors that can affect the equity of Athira Pharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Athira Pharma so important for investors?

The equity of Athira Pharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Athira Pharma take to change the equity?

To change equity, Athira Pharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Athira Pharma pay?

Over the past 12 months, Athira Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Athira Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Athira Pharma?

The current dividend yield of Athira Pharma is .

When does Athira Pharma pay dividends?

Athira Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Athira Pharma?

Athira Pharma paid dividends every year for the past 0 years.

What is the dividend of Athira Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Athira Pharma located?

Athira Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Athira Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Athira Pharma from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Athira Pharma pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Athira Pharma in the year 2023?

In the year 2023, Athira Pharma distributed 0 USD as dividends.

In which currency does Athira Pharma pay out the dividend?

The dividends of Athira Pharma are distributed in USD.